New Anticoagulant Pill Works Well in Trial
Lower doses safe and effective after heart attack and stroke WEDNESDAY, June 17 (HealthDay News) -- The new anti-clotting pill rivaroxaban (Xarelto) lowers the risk of stroke, heart attack and death in patients who have had a heart attack or suffer from unstable angina, a new trial sho...Afid Therapeutics Inc.'s New Anticoagulant Heparin Replacement Passes in Vivo Test
LANSING, Mich., Aug. 19 /PRNewswire/ -- Afid Therapeutics, Inc. announced today that it had completed successful in vitro and in vivo (whole animal) demonstrations of the efficacy of its new "traceless" anticoagulant, which is meant to replace heparin in many applications. The in vivo and some...Different anticoagulant regimens yield equal results
NEW YORK, NY DECEMBER 4, 2007 Patients with acute coronary syndromes (ACS) receiving early invasive treatment including angiography and percutaneous coronary intervention (PCI) have comparable results at 1 year in terms of mortality and ischemic outcomes no matter which of three different anticoa...'Artificial Golgi' may provide new insight into key cell structure
...nces that allow the body to function normally. The lab-on-a-chip device could lead to a faster and safer method for producing heparin, the widely used anticoagulant or blood thinner, the researchers note. Their study is scheduled for the Aug. 12 issue of the Journal of the American Chemical Society , a weekly pub...The risk of developing deep vein thrombosis during a flight is often overestimated
...medications that can be used." These so-called "anticoagulant" medications reduce the blood's ability to clot. Heparins are among the most established anticoagulant medications. They are injected subcutaneously (under the skin). ...Instrumentation Laboratory Receives 510(k) Clearance From FDA for HemosIL(R) Liquid Heparin Assay
...patients who undergo orthopedic, cardiovascular and other surgeries. UFH and LMWH monitoring is critical in assessing and determining the appropriate anticoagulant activity in these patients. Due to the extensive number of such patients, the availability of a chromogenic anti-Xa assay, readily and always availab...NORD to Honor Rare Disease Pioneers
...ive for seizures linked to Lennox-Gastaut syndrome, a severe form of childhood epilepsy GTC Biotherapeutics, Inc., for developing ATryn(R), an anticoagulant to prevent blood clots in people with a rare disease known as hereditary antithrombin (AT) deficiency Regeneron Pharmaceuticals, Inc., for dev...Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172
- Phase 2 development to begin in late 2008 or in early 2009 - SAN CARLOS, Calif., Aug. 14 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO ) today announced positive results from the Phase 1b proof-of-concept trial of NU172, demonstrating that the direct thrombin inhibitor rapidly p...Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
Orchid Pharma partners with Diakron MORRIS PLAINS, N.J., Aug. 13 /PRNewswire/ -- Diakron Pharmaceuticals, Inc. announced today the signing of an exclusive license agreement for a novel investigational oral anticoagulant drug candidate discovered and developed through Phase I ...Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
- Phase 2 trial expected to begin in late 2008 or early 2009 - SAN CARLOS, Calif., June 4 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO ) today announced that it has enrolled the first patient in a single-center, Phase 1b trial to determine the safety, tolerability and pharmacokin...Genetics Determine Optimal Drug Dose of Common Anticoagulant
WASHINGTON, Aug. 21 /PRNewswire-USNewswire/ -- Genetic testing can be used to help personalize the therapeutic dosage of warfarin, a commonly-used anticoagulant, according to research published in the September 1, 2007, issue of Blood, the journal of the American Society of Hematology. This re...Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative
...r sickest/costliest patients to coach patients and reduce hospitalizations. Palliative care program with physician home visits for homebound patients. anticoagulant management service has reduced adverse drug events by 26 percent. Peer Review and Teamwork for High-Value Care ...For Old or Young Dialysis Patients, AV Fistulas Remain Pure Gold
...s' other medical conditions -- such as whether they had peripheral arterial disease (PAD) or diabetes, whether they were smokers and whether they used anticoagulant medications -- to see how this information would play in the big picture. Elderly patients were more likely to be affected by these conditions; howeve...Nonspecific Circulating Anticoagulant Inhibitor PTT
Description: ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' client...Nonspecific Circulating Anticoagulant Inhibitor PT
Description: ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' client...Lupus Anticoagulant Panel with Reflex to 1:1 Mixes & Confirmations
Description: ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' client...Sonoclot Coagulation & Platelet Function Analyzer
Description:...e Sonoclot Analyzer is a versatile instrument for measuring coagulation and platelet function in whole blood or plasma. It is used worldwide to manage anticoagulant therapy, assess platelet function, control blood product usage, differentiate mechanical versus hemostatic bleeders, identify hypercoagulable and hepa...BD Vacutainer® Specialty Tubes - Acid Citrate Dextrose (ACD)
Features:... Whole blood tube with anticoagulant ACD Sol B ACD Sol A ...ACT PLUS Automated Coagulation Timer System
Features:... BUILT-IN EFFICIENCY Immediate results mean anticoagulant dosages can be adjusted quickly. Dual-well testing provides the extra confidence that only duplicate results provide. Because less than 1 ml of ...Genetics determine optimal drug dose of common anticoagulant
(WASHINGTON, August 21, 2007) Genetic testing can be used to help personalize the therapeutic dosage of warfarin, a commonly-used anticoagulant, according to research published in the September 1, 2007, issue of Blood , the journal of the American Society of Hematology. This result represents on...For old or young dialysis patients, AV fistulas remain pure gold
...ients' other medical conditionssuch as whether they had peripheral arterial disease (PAD) or diabetes, whether they were smokers and whether they used anticoagulant medicationsto see how this information would play in the big picture. Elderly patients were more likely to be affected by these conditions; however, t...UNC scientists teach enzyme to make synthetic heparin in more varieties
...sible for producing heparin, opening the door to a more effective synthetic anticoagulant as well as treatments for other conditions. Jian Liu, Ph.D., and collea...ed naturally by many creatures, including humans. As a drug, it is a common anticoagulant derived mainly from the intestinal lining of pigs. The manufactured form of...Findings released from 1 of the largest percutaneous coronary intervention trials ever
... drug therapy cardiologists choose for their patients with heart attack. HORIZONS-AMI is the largest study ever to focus on the appropriate use of anticoagulant medications in patients experiencing STEMI and undergoing primary percutaneous coronary intervention (PCI). Only 7.2 percent of patients in the bivali...Undergrad has sweet success with invention of artificial Golgi
... in the world. Heparin is formed naturally in the Golgi organelle in cells of the human body as well as in other animals like pigs. Heparin acts as an anticoagulant preventing blood clots, which makes it a good therapeutic for heart, stroke, and dialysis patients. The main source of heparin is currently the in...Clumps of red and white blood cells may contribute to sickle cell disease
... disrupted the aggregates because blood collection tubes usually contain an anticoagulant that ties up calcium, which often plays a role in cell adhesion. She saw the aggregates only when she used an anticoagulant that doesnt remove calcium. Brittain and her colleagues plan further stu...Safe and effective therapy discovered for patients with protein-losing enteropathy
...ate and prevents protein leakage in vitro. However, long-term therapy with anticoagulant heparin has severe side effects, including bleeding, thrombocytopenia and o...d in mice without causing bleeding. This compound exhibits greatly reduced anticoagulant activity, compared to unmodified heparin, which may mean that it can be use...Does the victim affect snake venom composition?
...w therapeutic strategies to treat human diseases," says Prof Kini from the Department of Biological Sciences, National University of Singapore. "A new anticoagulant or a hypotensive toxin may help us develop new cardiovascular drugs to block unwanted clot formation or to lower the blood pressure." ...Dogs keep dying: Many owners unaware of toxic dog food
...ing profile should assess the liver enzyme ALT to detect damage to the liver, serum cholesterol, total bilirubin concentration and the activity of the anticoagulant proteins antithrombin III (ATIII) and protein C. The coagulation protein tests, which have been adapted for dogs by Cornell researchers, have high val...Genetic variation alters response to common anti-clotting drug
... Millions of people take the anticoagulant drug warfarin to prevent harmful clotting after a heart attack, stroke, or ...of genetic variability truly improves patient treatment with this frontline anticoagulant drug." ...Regado Biosciences Expands Medical Advisory Board
...thrombotic technology platform, including the REG1 anticoagulant system as it enters phase 2b with the RADAR trial....ized medicine. Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents, th...can be used to completely or partially reverse the anticoagulant effect of RB006. Regado recently completed a phas...Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
...llowing conditions: pulmonary thromboembolism when anticoagulant therapy is contraindicated, failure of anticoagulant therapy in thromboembolic diseases, emergency trea...ollowing massive PE, and chronic recurrent PE when anticoagulant therapy has failed or is contraindicated. The niti...Regado Biosciences Establishes Medical Advisory Board
...r IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to completely or partially reverse the anticoagulant effect of RB006. Regado recently completed a phase 2a study of REG1 in percutaneous coronary intervention (PCI) and is planning the initiation of a r...ThromboGenics NV: Business Update
...ontinued to make considerable progress with our other key clinical and pre-clinical programs. We have begun a Phase II trial for our novel long-acting anticoagulant TB-402 and also received the first milestone from our strategic agreement with Roche for the novel anti-cancer agent TB-403. The development of Anti-V...ARCA biopharma to Present at 27th Annual JPMorgan Healthcare Conference
...portunity, as well as Nuvelo's mid-stage pipeline asset, novel short-acting anticoagulant NU172. In September 2008, the FDA formally accepted for filing ARCA's New D...which has completed Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and NU206, a Wnt pathway modulator i...Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
...d highly selective Factor IXa inhibitor and the second being its complementary reversal agent which can be used to completely or selectively lower the anticoagulant effects. The REG1 System is currently in Phase 2 clinical testing. ...